The FDA approved GSK antibiotic Blujepa as a treatment for uncomplicated urinary tract infections. The drug’s novel mechanism of action addresses a broader range of pathogens and could offer a way to lower the potential for drug resistance.
The post FDA Approves First-in-Class GSK Antibiotic for Common Type of Urinary Tract Infection appeared first on MedCity News.
